Why investors just put $315m behind AdvanCell’s prostate cancer alpha therapy
AdvanCell’s US$315 million Series D backs ADVC001 trials and Lead-212 manufacturing, but Phase 2 evidence remains the decisive test.
Pharma & Biotech